Implantica publishes Interim Report Q1, January-March 2021
“We would like to utilize the momentum in the digital industry and maintain the goal to be in the forefront of the eHealth transformation.”- Peter Forsell, CEO and Founder of ImplanticaSignificant events in the first quarter of 2021 · Implantica is able to sell RefluxStop™ in the UK with reimbursement and is now expanding the sales organization in the UK. · In Germany, Implantica has received its own Operation and Procedure Classification System (OPS) code and a reimbursement Diagnosis Related Group (DRG) for RefluxStop™. This is a milestone in Germany. · Applications for